It effectively inhibits CD39 enzymatic activity, resulting in elevated intratumoral ATP levels and significant tumor growth control in both MOLP8 murine xenograft models and cynomolgus monkeys, thereby supporting its clinical development [237]. This evidence concerns the gene ENTPD1 and neoplasm.